These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 32955172)

  • 1. Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
    Sweeney M; Corden B; Cook SA
    EMBO Mol Med; 2020 Oct; 12(10):e10865. PubMed ID: 32955172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved ejection fraction.
    Alex L; Russo I; Holoborodko V; Frangogiannis NG
    Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H934-H949. PubMed ID: 30004258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR4-dependent macrophage-to-fibroblast signaling contributes to cardiac diastolic dysfunction in heart failure with preserved ejection fraction.
    Zhang N; Ma Q; You Y; Xia X; Xie C; Huang Y; Wang Z; Ye F; Yu Z; Xie X
    Int J Biol Sci; 2022; 18(3):1271-1287. PubMed ID: 35173552
    [No Abstract]   [Full Text] [Related]  

  • 4. Characterization of a robust mouse model of heart failure with preserved ejection fraction.
    Matsiukevich D; Kovacs A; Li T; Kokkonen-Simon K; Matkovich SJ; Oladipupo SS; Ornitz DM
    Am J Physiol Heart Circ Physiol; 2023 Aug; 325(2):H203-H231. PubMed ID: 37204871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advance in the pharmacological and comorbidities management of heart failure with preserved ejection fraction: evidence from clinical trials.
    Meifang W; Ying W; Wen C; Kaizu X; Meiyan S; Liming L
    Heart Fail Rev; 2024 Mar; 29(2):305-320. PubMed ID: 37561223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship Between Focal and Diffuse Fibrosis Assessed by CMR and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.
    Kanagala P; Cheng ASH; Singh A; Khan JN; Gulsin GS; Patel P; Gupta P; Arnold JR; Squire IB; Ng LL; McCann GP
    JACC Cardiovasc Imaging; 2019 Nov; 12(11 Pt 2):2291-2301. PubMed ID: 30772227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telmisartan ameliorates cardiac fibrosis and diastolic function in cardiorenal heart failure with preserved ejection fraction.
    Chang D; Xu TT; Zhang SJ; Cai Y; Min SD; Zhao Z; Lu CQ; Wang YC; Ju S
    Exp Biol Med (Maywood); 2021 Dec; 246(23):2511-2521. PubMed ID: 34342551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of heart failure with preserved ejection fraction (HFpEF): reexamining microRNA-21 inhibition in the era of oligonucleotide-based therapeutics.
    Ben-Nun D; Buja LM; Fuentes F
    Cardiovasc Pathol; 2020; 49():107243. PubMed ID: 32629211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAX1BP1 downregulation by STAT3 in cardiac fibroblasts contributes to diabetes-induced heart failure with preserved ejection fraction.
    Zuo GF; Wang LG; Huang L; Ren YF; Ge Z; Hu ZY; Zhang JJ; Chen SL
    Biochim Biophys Acta Mol Basis Dis; 2024 Feb; 1870(2):166979. PubMed ID: 38065272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart failure with preserved ejection fraction (HFpEF) pathophysiology study (IDENTIFY-HF): does increased arterial stiffness associate with HFpEF, in addition to ageing and vascular effects of comorbidities? Rationale and design.
    Ali D; Callan N; Ennis S; Powell R; McGuire S; McGregor G; Weickert MO; Miller MA; Cappuccio FP; Banerjee P
    BMJ Open; 2019 Nov; 9(11):e027984. PubMed ID: 31748285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocardial fibrosis and prognosis in heart failure with preserved ejection fraction: a pooled analysis of 12 cohort studies.
    Zhang X; Yang S; Hao S; Li J; Qiu M; Chen H; Huang Y
    Eur Radiol; 2024 Mar; 34(3):1854-1862. PubMed ID: 37658896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments.
    Olivotto I; Udelson JE; Pieroni M; Rapezzi C
    Eur Heart J; 2023 Feb; 44(8):656-667. PubMed ID: 36582184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiomyocyte Functional Etiology in Heart Failure With Preserved Ejection Fraction Is Distinctive-A New Preclinical Model.
    Curl CL; Danes VR; Bell JR; Raaijmakers AJA; Ip WTK; Chandramouli C; Harding TW; Porrello ER; Erickson JR; Charchar FJ; Kompa AR; Edgley AJ; Crossman DJ; Soeller C; Mellor KM; Kalman JM; Harrap SB; Delbridge LMD
    J Am Heart Assoc; 2018 Jun; 7(11):. PubMed ID: 29858360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel fibroblast activation inhibitor attenuates left ventricular remodeling and preserves cardiac function in heart failure.
    Bradley JM; Spaletra P; Li Z; Sharp TE; Goodchild TT; Corral LG; Fung L; Chan KWH; Sullivan RW; Swindlehurst CA; Lefer DJ
    Am J Physiol Heart Circ Physiol; 2018 Sep; 315(3):H563-H570. PubMed ID: 29949382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sudden death in heart failure with preserved ejection fraction and beyond: an elusive target.
    Manolis AS; Manolis AA; Manolis TA; Melita H
    Heart Fail Rev; 2019 Nov; 24(6):847-866. PubMed ID: 31147814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ca2+ entry mode of Na+/Ca2+ exchanger as a new therapeutic target for heart failure with preserved ejection fraction.
    Kamimura D; Ohtani T; Sakata Y; Mano T; Takeda Y; Tamaki S; Omori Y; Tsukamoto Y; Furutani K; Komiyama Y; Yoshika M; Takahashi H; Matsuda T; Baba A; Umemura S; Miwa T; Komuro I; Yamamoto K
    Eur Heart J; 2012 Jun; 33(11):1408-16. PubMed ID: 21490055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulation in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives.
    Kessler EL; Oerlemans MIFJ; van den Hoogen P; Yap C; Sluijter JPG; de Jager SCA
    J Cardiovasc Transl Res; 2021 Feb; 14(1):63-74. PubMed ID: 32444946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-181c targets Parkin and SMAD7 in human cardiac fibroblasts: Validation of differential microRNA expression in patients with diabetes and heart failure with preserved ejection fraction.
    Jankauskas SS; Mone P; Avvisato R; Varzideh F; De Gennaro S; Salemme L; Macina G; Kansakar U; Cioppa A; Frullone S; Gambardella J; Di Mauro M; Tesorio T; Santulli G
    Mech Ageing Dev; 2023 Jun; 212():111818. PubMed ID: 37116731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future.
    Wintrich J; Kindermann I; Ukena C; Selejan S; Werner C; Maack C; Laufs U; Tschöpe C; Anker SD; Lam CSP; Voors AA; Böhm M
    Clin Res Cardiol; 2020 Sep; 109(9):1079-1098. PubMed ID: 32236720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Heart Failure with Preserved Ejection Fraction.
    Ilieșiu AM; Hodorogea AS
    Adv Exp Med Biol; 2018; 1067():67-87. PubMed ID: 29498023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.